Europe CIN & HR-HPV Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Disease Type (Cervical Intraepithelial Neoplasia 1, Cervical Intraepithelial Neoplasia 2, and Cervical Intraepithelial Neoplasia 3), Strain Type (HPV 16, HPV 18, and Others), Offering (Diagnostic Method and Treatment), Product Type (Kits & Reagents, Instruments, and Services), and End User (Hospitals & Clinics, Diagnostic Laboratories, Specialized Clinical Laboratories, and Others)
The Europe CIN & HR-HPV treatment market is expected to grow from US$ 3,771.58 million in 2023 to US$ 5119.63 million by 2028. It is estimated to grow at a CAGR of 6.3% from 2023 to 2028.
Increase in Prevalence of Human Papillomavirus Infections Fuels Europe CIN & HR-HPV Treatment Market
Cervical intraepithelial neoplasia (CIN), also called cervical dysplasia, is characterized by the formation of proliferative lesions with abnormal cell growth on the surface of the cervix. These lesions replace a part of or the entire cervical squamous epithelium, and they are perceived as precursors of cervical cancer. Cervical dysplasia is caused by human papillomavirus (HPV) infection. Over 200 variants of HPV are known to cause infections among humans, and ~40 of these variants affect genitals upon spreading through sexual contact. 12 of these HPV types are associated with a high risk of cancer, and ~10 are associated with low risk cancer. ~70% of cervical cancer cases are caused by HPV type 16 and type 18, which are high-risk HPV (HR-HPV) serotypes. According to a study published in the National Library of Medicine, in 2022, most cervical cancer cases were caused by HPV 16, accounting for 55–60% of cervical cancer cases reported across the region in that year. Moreover, HPV 18 accounts for 10–15% of cervical cancer cases in the world. A persistent HPV infection can result in CIN among subjects that are immunocompromised and infected with HIV and have a history of smoking. According to the European Cancer Organization, in 2020, HPV infections were the cause of ~2.5% of cancer cases in Europe, and the prevalence of high-risk HPV infection exceeds 15% among the European population. According to the World Health Organization, ~66,000 women were diagnosed with cervical cancer in the WHO European region in 2022.
Thus, a rise in the prevalence of HPV infections contributes to the growth of the Europe CIN & HR-HPV treatment market.
Europe CIN & HR-HPV Treatment Market Overview
The Europe CIN & HR-HPV treatment market is divided into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a market share of the Europe CIN & HR-HPV treatment market, and it is estimated to register a robust growth rate during the forecast period. The growth of the CIN & HR-HPV treatment market in Europe is attributed due to the high incidence of cervical cancer and the increase in cervical cancer screening programs
Europe CIN & HR-HPV Treatment Market Revenue and Forecast to 2028 (US$ Million)
Europe CIN & HR-HPV Treatment Market Segmentation
The Europe CIN & HR-HPV treatment market is segmented into disease type, strain type, offering, product type,end user, and country.
Based on disease type, the market is segmented into cervical intraepithelial neoplasia 1 (CIN 1), cervical intraepithelial neoplasia 2 (CIN 2), and cervical intraepithelial neoplasia 3 (CIN 3). The cervical intraepithelial neoplasia 3 (CIN 3) segment registered the largest market share in 2023.
Based on strain type, the Europe CIN & HR-HPV treatment market is segmented into HPV 16, HPV 18, and others. The HPV 16 segment held the largest market share in 2023.
Based on offering, the Europe CIN & HR-HPV treatment market is bifurcated into diagnostic methods and treatments. The treatments segment held a larger market share in 2023. Further, diagnostic methods are segmented into pap smear, HPV testing, colposcopy, and biopsy. Further, treatments are bifurcated into excision surgery and ablation techniques.
Based on product type, the market is segmented into kits & reagents, instruments, and services. The services segment held the largest market share in 2023.
Based on end user, the Europe CIN & HR-HPV treatment market is segmented into hospitals & clinics, diagnostic laboratories, specialized clinical laboratories, and others. The hospitals & clinics segment held the largest market share in 2023.
Based on country, the Europe CIN & HR-HPV treatment market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the market share in 2022.
Fujirebio Europe NV; Qiagen NV; Zilico Ltd; Abbott Laboratories; F. Hoffmann-LA Roche Ltd; Bioneer Corp; and Thermo Fisher Scientific Inc are the leading companies operating in the CIN & HR-HPV treatment market in the region.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe CIN & HR-HPV Market – by Disease Type
1.3.2 Europe CIN & HR-HPV Market – by Strain Type
1.3.3 Europe CIN & HR-HPV Market – by Offering
1.3.4 Europe CIN & HR-HPV Market – by Product Type
1.3.5 Europe CIN & HR-HPV Market – by End User
1.3.6 Europe CIN & HR-HPV Market – by Country
2. Europe CIN & HR-HPV Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe CIN & HR-HPV Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Europe PEST Analysis
4.3 Expert’s Opinion
5. Europe CIN & HR-HPV Treatment Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Prevalence of Human Papillomavirus Infections
5.1.2 Favourable Initiatives for Preventing Cervical Cancer
5.2 Market Restraints
5.2.1 Increased Reoccurrence Rate and High Cost of CIN & HR-HPV Treatment
5.3 Market Opportunities
5.3.1 Development and Launch of Innovative Products
5.4 Future Trends
5.4.1 Use of Modern Technologies in CIN & HR-HPV Screening and Diagnosis
5.5 Impact Analysis
6. CIN & HR-HPV Market – Europe Analysis
6.1 Europe CIN & HR-HPV Market Revenue Forecast and Analysis
7. Europe CIN and HR-HPV Treatment Market Revenue and Forecasts To 2028– by Disease Type
7.1 Overview
7.2 Europe CIN and HR-HPV Treatment Market, By disease type, 2022 & 2028 (%)
7.3 CIN 1
7.3.1 Overview
7.3.2 CIN 1: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
7.4 CIN 2
7.4.1 Overview
7.4.2 CIN 2: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
7.5 CIN 3
7.5.1 Overview
7.5.2 CIN 3: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
8. Europe CIN and HR-HPV Treatment Market Revenue and Forecasts To 2028– by Strain Type
8.1 Overview
8.2 Europe CIN and HR-HPV Treatment Market, By Strain Type, 2022 & 2028 (%)
8.4 HPV 16
8.4.1 Overview
8.4.2 HPV 16: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
8.5 HPV 18
8.5.1 Overview
8.5.2 HPV 18: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
9. Europe CIN and HR-HPV Treatment Market Revenue and Forecasts To 2028– by Offering
9.1 Overview
9.2 Europe CIN and HR-HPV Treatment Market, By Offering, 2022 & 2028 (%)
9.4 Diagnostic Method
9.4.1 Overview
9.4.2 Diagnostic Method: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
9.4.3 Pap Smear
9.4.3.1 Overview
9.4.3.2 Pap Smear: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
9.4.4 HPV Testing
9.4.4.1 Overview
9.4.4.2 HPV Testing: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5 Colposcopy
9.4.5.1 Overview
9.4.5.2 Colposcopy: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
9.4.6 Biopsy
9.4.6.1 Overview
9.4.6.2 Biopsy: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
9.5 Treatment
9.5.1 Overview
9.5.2 Treatment: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
9.5.2.1 Excision Surgery
9.5.2.1.1 Overview
9.5.2.1.2 Excision Surgery: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
9.5.2.2 Ablation Techniques
9.5.2.2.1 Overview
9.5.2.2.2 Ablation Techniques: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
10. Europe CIN & HR-HPV Treatment Market Analysis and Forecast to 2028 – by Product Type
10.1 Overview
10.2 Europe CIN & HR-HPV Treatment Market, by Product Type 2022 & 2028 (%)
10.3 Kits & Reagents
10.3.1 Overview
10.3.2 Kits & Reagents: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Instrument
10.4.1 Overview
10.4.2 Instrument: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
10.5 Services
10.5.1 Overview
10.5.2 Services: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11. Europe CIN & HR-HPV Treatment Market Analysis and Forecast to 2028 – by End User
11.1 Overview
11.2 Europe CIN & HR-HPV Treatment Market, by End User 2022 & 2028 (%)
11.3 Hospital & Clinics
11.3.1 Overview
11.3.2 Hospital & Clinics: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.4 Diagnostic Laboratories
11.4.1 Overview
11.4.2 Diagnostic Laboratories: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.5 Specialized Clinical Laboratories
11.5.1 Overview
11.5.2 Specialized Clinical Laboratories: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.6 Others
11.6.1 Overview
11.6.2 Others: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12. Europe CIN & HR-HPV Treatment Market Revenue and Forecasts to 2028 – Country Analysis
12.1 Europe: CIN & HR-HPV Treatment Market
12.1.1 Overview
12.1.2 Europe: CIN & HR-HPV Treatment Market, by Country, 2022 & 2028 (%)
12.1.2.1 Germany: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.1.1 Overview
12.1.2.1.2 Germany: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.1.3 Germany: CIN & HR-HPV Treatment Market, by Disease Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.1.4 Germany: CIN & HR-HPV Treatment Market, by Strain Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.1.5 Germany: CIN & HR-HPV Treatment Market, by Offerings – Revenue and Forecast to 2028 (US$ Million)
12.1.2.1.5.1 Germany: CIN & HR-HPV Treatment Market, by Diagnostic Methods – Revenue and Forecast to 2028 (US$ Million)
12.1.2.1.5.2 Germany: CIN & HR-HPV Treatment Market, by Treatments – Revenue and Forecast to 2028 (US$ Million)
12.1.2.1.6 Germany: CIN & HR-HPV Treatment Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.1.7 Germany: CIN & HR-HPV Treatment Market, by End Users – Revenue and Forecast to 2028 (US$ Million)
12.1.2.2 France: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.2.1 Overview
12.1.2.2.2 France: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.2.3 France: CIN & HR-HPV Treatment Market, by Disease Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.2.4 France: CIN & HR-HPV Treatment Market, by Strain Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.2.5 France: CIN & HR-HPV Treatment Market, by Offerings – Revenue and Forecast to 2028 (US$ Million)
12.1.2.2.5.1 France: CIN & HR-HPV Treatment Market, by Diagnostic Methods – Revenue and Forecast to 2028 (US$ Million)
12.1.2.2.5.2 France: CIN & HR-HPV Treatment Market, by Treatments – Revenue and Forecast to 2028 (US$ Million)
12.1.2.2.6 France: CIN & HR-HPV Treatment Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.2.7 France: CIN & HR-HPV Treatment Market, by End Users – Revenue and Forecast to 2028 (US$ Million)
12.1.2.3 UK: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.3.1 Overview
12.1.2.3.2 UK: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.3.3 UK: CIN & HR-HPV Treatment Market, by Disease Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.3.4 UK: CIN & HR-HPV Treatment Market, by Strain Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.3.5 UK: CIN & HR-HPV Treatment Market, by Offerings – Revenue and Forecast to 2028 (US$ Million)
12.1.2.3.5.1 UK: CIN & HR-HPV Treatment Market, by Diagnostic Methods – Revenue and Forecast to 2028 (US$ Million)
12.1.2.3.5.2 UK: CIN & HR-HPV Treatment Market, by Treatments – Revenue and Forecast to 2028 (US$ Million)
12.1.2.3.6 UK: CIN & HR-HPV Treatment Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.3.7 UK: CIN & HR-HPV Treatment Market, by End Users – Revenue and Forecast to 2028 (US$ Million)
12.1.2.4 Italy: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.4.1 Overview
12.1.2.4.2 Italy: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.4.3 Italy: CIN & HR-HPV Treatment Market, by Disease Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.4.4 Italy: CIN & HR-HPV Treatment Market, by Strain Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.4.5 Italy: CIN & HR-HPV Treatment Market, by Offerings – Revenue and Forecast to 2028 (US$ Million)
12.1.2.4.5.1 Italy: CIN & HR-HPV Treatment Market, by Diagnostic Methods – Revenue and Forecast to 2028 (US$ Million)
12.1.2.4.5.2 Italy: CIN & HR-HPV Treatment Market, by Treatments – Revenue and Forecast to 2028 (US$ Million)
12.1.2.4.6 Italy: CIN & HR-HPV Treatment Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.4.7 Italy: CIN & HR-HPV Treatment Market, by End Users – Revenue and Forecast to 2028 (US$ Million)
12.1.2.5 Spain: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.5.1 Overview
12.1.2.5.2 Spain: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.5.3 Spain: CIN & HR-HPV Treatment Market, by Disease Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.5.4 Spain: CIN & HR-HPV Treatment Market, by Strain Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.5.5 Spain: CIN & HR-HPV Treatment Market, by Offerings – Revenue and Forecast to 2028 (US$ Million)
12.1.2.5.5.1 Spain: CIN & HR-HPV Treatment Market, by Diagnostic Methods – Revenue and Forecast to 2028 (US$ Million)
12.1.2.5.5.2 Spain: CIN & HR-HPV Treatment Market, by Treatments – Revenue and Forecast to 2028 (US$ Million)
12.1.2.5.6 Spain: CIN & HR-HPV Treatment Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.5.7 Spain: CIN & HR-HPV Treatment Market, by End User– Revenue and Forecast to 2028 (US$ Million)
12.1.2.6 Rest of Europe: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.6.1 Overview
12.1.2.6.2 Rest of Europe: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.2.6.3 Rest of Europe: CIN & HR-HPV Treatment Market, by Disease Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.6.4 Rest of Europe: CIN & HR-HPV Treatment Market, by Strain Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.6.5 Rest of Europe: CIN & HR-HPV Treatment Market, by Offerings – Revenue and Forecast to 2028 (US$ Million)
12.1.2.6.5.1 Rest of Europe: CIN & HR-HPV Treatment Market, by Diagnostic Methods – Revenue and Forecast to 2028 (US$ Million)
12.1.2.6.5.2 Rest of Europe: CIN & HR-HPV Treatment Market, by Treatments – Revenue and Forecast to 2028 (US$ Million)
12.1.2.6.6 Rest of Europe: CIN & HR-HPV Treatment Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
12.1.2.6.7 Rest of Europe: CIN & HR-HPV Treatment Market, by End Users – Revenue and Forecast to 2028 (US$ Million)
13. Europe CIN & HR-HPV Treatment Market – Industry Landscape
13.1 Overview
13.2 Growth Strategies in CIN & HR-HPV Treatment Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Fujirebio Europe NV
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 .Key Developments
14.2 Qiagen NV
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Zilico Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Abbott Laboratories
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 F. Hoffmann-La Roche Ltd
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Bioneer Corp
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Thermo Fisher Scientific Inc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
LIST OF TABLES
Table 1. Germany: CIN & HR-HPV Treatment Market, by Disease Type – Revenue and Forecast to 2028 (US$ Million)
Table 2. Germany: CIN & HR-HPV Treatment Market, by Strain Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. Germany: CIN & HR-HPV Treatment Market, by Offerings – Revenue and Forecast to 2028 (US$ Million)
Table 4. Germany: CIN & HR-HPV Treatment Market, by Diagnostic Methods – Revenue and Forecast to 2028 (US$ Million)
Table 5. Germany: CIN & HR-HPV Treatment Market, by Treatments – Revenue and Forecast to 2028 (US$ Million)
Table 6. Germany: CIN & HR-HPV Treatment Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 7. Germany: CIN & HR-HPV Treatment Market, by End Users – Revenue and Forecast to 2028 (US$ Million)
Table 8. Burden of Cervical HPV Infection in France
Table 9. France: CIN & HR-HPV Treatment Market, by Disease Type – Revenue and Forecast to 2028 (US$ Million)
Table 10. France: CIN & HR-HPV Treatment Market, by Strain Type – Revenue and Forecast to 2028 (US$ Million)
Table 11. France: CIN & HR-HPV Treatment Market, by Offerings – Revenue and Forecast to 2028 (US$ Million)
Table 12. France: CIN & HR-HPV Treatment Market, by Diagnostic Methods – Revenue and Forecast to 2028 (US$ Million)
Table 13. France: CIN & HR-HPV Treatment Market, by Treatments – Revenue and Forecast to 2028 (US$ Million)
Table 14. France: CIN & HR-HPV Treatment Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 15. France: CIN & HR-HPV Treatment Market, by End Users – Revenue and Forecast to 2028 (US$ Million)
Table 16. Burden of Cervical Cancer in UK
Table 17. UK: CIN & HR-HPV Treatment Market, by Disease Type – Revenue and Forecast to 2028 (US$ Million)
Table 18. UK: CIN & HR-HPV Treatment Market, by Strain Type – Revenue and Forecast to 2028 (US$ Million)
Table 19. UK: CIN & HR-HPV Treatment Market, by Offerings – Revenue and Forecast to 2028 (US$ Million)
Table 20. UK: CIN & HR-HPV Treatment Market, by Diagnostic Methods – Revenue and Forecast to 2028 (US$ Million)
Table 21. UK: CIN & HR-HPV Treatment Market, by Treatments – Revenue and Forecast to 2028 (US$ Million)
Table 22. UK: CIN & HR-HPV Treatment Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 23. UK: CIN & HR-HPV Treatment Market, by End Users – Revenue and Forecast to 2028 (US$ Million)
Table 24. Crude Incidence Rates of HPV-Related Cancer Types in Italy
Table 25. Italy: CIN & HR-HPV Treatment Market, by Disease Type – Revenue and Forecast to 2028 (US$ Million)
Table 26. Italy: CIN & HR-HPV Treatment Market, by Strain Type – Revenue and Forecast to 2028 (US$ Million)
Table 27. Italy: CIN & HR-HPV Treatment Market, by Offerings – Revenue and Forecast to 2028 (US$ Million)
Table 28. Italy: CIN & HR-HPV Treatment Market, by Diagnostic Methods – Revenue and Forecast to 2028 (US$ Million)
Table 29. Italy: CIN & HR-HPV Treatment Market, by Treatments – Revenue and Forecast to 2028 (US$ Million)
Table 30. Italy: CIN & HR-HPV Treatment Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 31. Italy: CIN & HR-HPV Treatment Market, by End Users – Revenue and Forecast to 2028 (US$ Million)
Table 32. Spain: CIN & HR-HPV Treatment Market, by Disease Type – Revenue and Forecast to 2028 (US$ Million)
Table 33. Spain: CIN & HR-HPV Treatment Market, by Strain Type – Revenue and Forecast to 2028 (US$ Million)
Table 34. Spain: CIN & HR-HPV Treatment Market, by Offerings – Revenue and Forecast to 2028 (US$ Million)
Table 35. Spain: CIN & HR-HPV Treatment Market, by Diagnostic Methods – Revenue and Forecast to 2028 (US$ Million)
Table 36. Spain: CIN & HR-HPV Treatment Market, by Treatments – Revenue and Forecast to 2028 (US$ Million)
Table 37. Spain: CIN & HR-HPV Treatment Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 38. Spain: CIN & HR-HPV Treatment Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 39. Rest of Europe: CIN & HR-HPV Treatment Market, by Disease Type – Revenue and Forecast to 2028 (US$ Million)
Table 40. Rest of Europe: CIN & HR-HPV Treatment Market, by Strain Type – Revenue and Forecast to 2028 (US$ Million)
Table 41. Rest of Europe: CIN & HR-HPV Treatment Market, by Offerings – Revenue and Forecast to 2028 (US$ Million)
Table 42. Rest of Europe: CIN & HR-HPV Treatment Market, by Diagnostic Methods – Revenue and Forecast to 2028 (US$ Million)
Table 43. Rest of Europe: CIN & HR-HPV Treatment Market, by Treatments – Revenue and Forecast to 2028 (US$ Million)
Table 44. Rest of Europe: CIN & HR-HPV Treatment Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 45. Rest of Europe: CIN & HR-HPV Treatment Market, by End Users – Revenue and Forecast to 2028 (US$ Million)
Table 46. Recent Organic Growth Strategies in CIN & HR-HPV Treatment Market
Table 47. Recent Inorganic Growth Strategies in the CIN & HR-HPV Treatment Market
Table 48. Glossary of Terms
LIST OF FIGURES
Figure 1. Europe CIN & HR-HPV Market Segmentation
Figure 2. Europe CIN & HR-HPV Market, by Country
Figure 3. Europe CIN & HR-HPV Market Overview
Figure 4. Cervical Intraepithelial Neoplasia 3 Segment Held Largest Share of Disease Type Segment in CIN & HR-HPV Market
Figure 5. Germany Expected to Show Remarkable Growth During Forecast Period
Figure 6. Europe: PEST Analysis
Figure 7. Europe Experts’ Opinion
Figure 8. Europe CIN & HR-HPV Market: Impact Analysis of Drivers and Restraints
Figure 9. Europe CIN & HR-HPV Market – Revenue Forecast and Analysis – 2020–2028
Figure 10. Europe CIN and HR-HPV Treatment Market, by disease type, 2022 & 2028 (%)
Figure 11. CIN 1: Europe CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. CIN 2: Europe CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. CIN 3: Europe CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
Figure 14. Europe CIN and HR-HPV Treatment Market, by Strain Type, 2022 & 2028 (%)
Figure 15. HPV 16: Europe CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
Figure 16. HPV 18: Europe CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
Figure 17. Others: Europe CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
Figure 18. Europe CIN and HR-HPV Treatment Market, by offering, 2022 & 2028 (%)
Figure 19. Diagnostic Method: Europe CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
Figure 20. Pap Smear: Europe CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. HPV Testing: Europe CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Colposcopy: Europe CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Biopsy: Europe CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
Figure 24. Treatment: Europe CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
Figure 25. Excision Surgery: Europe CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
Figure 26. Ablation Techniques: Europe CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
Figure 27. Europe CIN & HR-HPV Treatment Market, by Product Type 2022 & 2028 (%)
Figure 28. Kits & Reagents: Europe CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Instrument: Europe CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Services: Europe CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Europe CIN & HR-HPV Treatment Market, by End User 2022 & 2028 (%)
Figure 32. Hospital & Clinics: Europe CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Diagnostic Laboratories: Europe CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Specialized Clinical Laboratories: Europe CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Others: Europe CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Europe: CIN & HR-HPV Treatment Market, by Key Country – Revenue (2022) (US$ Million)
Figure 37. Europe: CIN & HR-HPV Treatment Market, by Country, 2022 & 2028 (%)
Figure 38. Germany: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. France: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. UK: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. Italy: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 42. Spain: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 43. Rest of Europe: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 44. Growth Strategies in CIN & HR-HPV Treatment Market
- Fujirebio Europe NV
- Qiagen NV
- Zilico Ltd
- Abbott Laboratories
- F. Hoffmann-LA Roche Ltd
- Bioneer Corp
- Thermo Fisher Scientific Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe CIN & HR-HPV treatment market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe CIN & HR-HPV treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the CIN & HR-HPV treatment market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.